N- and C-terminal structure-activity study of angiotensin II on the angiotensin AT2 receptor

被引:30
作者
Bouley, R [1 ]
Pérodin, J [1 ]
Plante, H [1 ]
Rihakova, L [1 ]
Bernier, SG [1 ]
Maletínská, L [1 ]
Guillemette, G [1 ]
Escher, E [1 ]
机构
[1] Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada
基金
英国医学研究理事会;
关键词
angiotensin II; angiotensin AT(1) receptor; angiotensin AT(2) receptor; myometrium;
D O I
10.1016/S0014-2999(97)01549-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The predominant angiotensin II receptor expressed in the human myometrium is the angiotensin AT(2) receptor. This preparation was used for a structure-activity relationship study on angiotensin II analogues modified in positions 1 and 8. The angiotensin AT(2) receptor present on human myometrium membranes displayed a high affinity (pK(d) = 9.18) and was relatively abundant (53-253 fmol/mg of protein). The pharmacological profile was typical of an angiotensin AT(2) receptor with the following order of affinities: (angiotensin III greater than or equal to angiotensin II > angiotensin I > PD123319 > angiotensin-(1-7) > angiotensin-(1-6) approximate to angiotensin IV >> Losartan). Modifications of the N-terminal side chain and of the primary amine of angiotensin II were evaluated. Neutralisation of the methylcarboxylate (Asp) to a methylcarboxamide (Asn) or to a hydroxymethyl (Ser) or substitution for a methylsulfonate group (cysteic acid) improved the affinity. Extension from methylcarboxylate (Asp) to ethylcarboxylate (Glu) did not affect the affinity. Introduction of larger side chains such as the bulky p-benzoylphenylalanine (p-Bpa) or the positively charged Lys did not substantially affect the affinity. Complete removal of the side chain (angiotensin III), however, resulted in a significant affinity increase. Removal or acetylation of the primary amine of angiotensin II did not noticeably influence the affinity. Progressive alkylation of the primary amine significantly increased the affinity, betain structures being the most potent. It appears that quite important differences exist between the angiotensin AT(1) and AT(2) receptors concerning their pharmacological profile towards analogues of angiotensin II modified in position 1. On position 8 of angiotensin II, a structure-activity relationship on the angiotensin AT(2) receptor was quite similar to that observed with angiotensin AT(1) receptor. Bulky, hydrophobic aromatic residues displayed affinities similar to or even better than [Sarcosine(1)]angiotensin II. Aliphatic residues, especially those of reduced size, caused a significant decrease in affinity especially [Sarcosine(1), Gly(8)]angiotensin II who showed a 30-fold decrease. Introduction of a positive charge (Lys) at position 8 reduced the affinity even further. Stereoisomers in position 8 (L --> D configuration) also induced lower affinities. The angiotensin AT(2) receptor display a structure-activity relationship similar to that observed on the AT(1) receptor for the C-terminal position of the peptide hormone. Position 1 structure-activity relationships are however fundamentally different between the angiotensin AT(1) and AT(2) receptor. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:323 / 331
页数:9
相关论文
共 42 条
[1]   ANGIOTENSIN-II AT2 RECEPTORS DO NOT INTERACT WITH GUANINE-NUCLEOTIDE BINDING-PROTEINS [J].
BOTTARI, SP ;
TAYLOR, V ;
KING, IN ;
BOGDAL, Y ;
WHITEBREAD, S ;
DEGASPARO, M .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1991, 207 (02) :157-163
[2]   Characterization of a specific binding site for angiotensin II in chicken liver [J].
Bouley, R ;
Gosselin, A ;
Plante, H ;
Servant, G ;
Perodin, J ;
Arcand, M ;
Guillemette, G ;
Escher, E .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1997, 75 (06) :568-575
[3]   NOMENCLATURE FOR ANGIOTENSIN RECEPTORS - A REPORT OF THE NOMENCLATURE-COMMITTEE OF THE COUNCIL-FOR-HIGH-BLOOD-PRESSURE-RESEARCH [J].
BUMPUS, FM ;
CATT, KJ ;
CHIU, AT ;
DEGASPARO, M ;
GOODFRIEND, T ;
HUSAIN, A ;
PEACH, MJ ;
TAYLOR, DG ;
TIMMERMANS, PBMWM .
HYPERTENSION, 1991, 17 (05) :720-721
[4]  
CHANG RSL, 1990, MOL PHARMACOL, V37, P347
[5]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]   IDENTIFICATION OF ANGIOTENSIN-II RECEPTOR SUBTYPES [J].
CHIU, AT ;
HERBLIN, WF ;
MCCALL, DE ;
ARDECKY, RJ ;
CARINI, DJ ;
DUNCIA, JV ;
PEASE, LJ ;
WONG, PC ;
WEXLER, RR ;
JOHNSON, AL ;
TIMMERMANS, PBMWM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 165 (01) :196-203
[7]   Angiotensin II receptor characteristics and subtype expression in uterine arteries and myometrium during pregnancy [J].
Cox, BE ;
Word, RA ;
Rosenfeld, CR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (01) :49-58
[8]   BINDING CHARACTERISTICS AND VASCULAR EFFECTS OF VARIOUS ANGIOTENSIN-II ANTAGONISTS [J].
CRISCIONE, L ;
THOMANN, H ;
WHITEBREAD, S ;
DEGASPARO, M ;
BUHLMAYER, P ;
HEROLD, P ;
OSTERMAYER, F ;
KAMBER, B .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 16 :S56-S59
[9]  
DUDLEY DT, 1991, MOL PHARMACOL, V40, P360
[10]   PHOTOAFFINITY LABELING OF THE ANGIOTENSIN-II RECEPTOR - PHARMACOLOGY OF THE LABELING PEPTIDES IN THE DARK [J].
ESCHER, E ;
NGUYEN, TMD ;
REGOLI, D .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1978, 56 (06) :956-962